Dosimetric Approach in Metastatic Differentiated Thyroid Cancer and Hyperthyroidism

Abstract

Radioiodine (¹³¹I) therapy has been widely used for well-differentiated thyroid cancer and its metastases for many years. Two approaches, namely, empirical dosage and dosimetry-based methods, are currently utilized to manage the therapeutic iodine activity.

Empirical dosage is based on the physician’s rating to suggest appropriate activity within a certain range of without individualized dose planning. On the other hand, dosimetry-based approach implicates effective activity administration leaning on specific activity regulated by the organs at risk.

In this report, we propose and define dosimetry-based treatment with examples of differentiated thyroid cancer and hyperthyroidism cases.

Our results indicated that the implementation of dosimetry protocol might help to administer larger amounts of activity controlled by critical organ dose limits, thereby delivering lethal dose to tumors with no toxicity. It is also well demonstrated that dosimetric approach is favorable for hyperthyroid patients in order to deliver right amount of radioiodine activity for efficient therapeutical response.